A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05536804 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Obesity
Chronic Kidney Disease
Type 2 Diabetes
T2D

Interventions

DRUG: Tirzepatide
DRUG: Placebo

Sponsor

Eli Lilly and Company